CYB004 is being evaluated for the treatment of patients with generalised anxiety disorder. Credit: Kmpzzz via Shutterstock.com.

Cybin has dosed the first healthy volunteers in the ongoing Part C of Phase I study of CYB004 to treat generalised anxiety disorder.

CYB004 is a deuterated dimethyltryptamine (dDMT) molecule that activates the 5-HT2A receptor and has the potential to overcome existing DMT limitations.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Part C is a part of the CYB004-E Phase I trial, which is designed to evaluate the safety, pharmacokinetic and pharmacodynamic of escalating CYB004 doses against DMT in healthy volunteers.

Parts A and B of the Phase I study were completed earlier.

The crossover Part C study will assess IV bolus along with infusion regimens of CYB004 in up to two cohorts.

Psychedelic effects were observed within two minutes and reached a peak at about 13 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

No safety concerns were observed in the initial participants.

Findings from Part C and the completed Part B will be used to decide the formulation and optimal dosing for further CYB004 clinical studies.

Cybin CEO Doug Drysdale said: “We plan to leverage these findings to support our goal of developing a differentiated psychedelic-based therapeutic with an optimal treatment profile that may offer less invasive and more convenient dosing methods to provide new and improved treatment options for patients and providers.

“We are proud of the speed in which we have advanced this CYB004 programme and look forward to sharing topline results later this year, along with additional topline efficacy data from our lead clinical programme, CYB003, which is currently being studied in patients with Major Depressive Disorder.

Being conducted at the Centre for Human Drug Research in the Netherlands, the CYB004-E study is said to be one of the largest Phase I DMT clinical trials till date.

CYB004 is protected by a US composition of matter patent through 2041.